grant
A novel therapeutic strategy to target mutant p53
Organization UNIVERSITY OF CALIFORNIA AT DAVISLocation DAVIS, UNITED STATESPosted 1 Mar 2025Deadline 28 Feb 2030
NIHUS FederalResearch GrantFY2026AccelerationAdjuvantAnti-OncogenesAntioncogene Protein p53AntioncogenesAttenuatedBasal Transcription FactorBasal transcription factor genesBindingBiological MarkersCDK4CDK4 geneCancer PrognosisCancer Suppressor GenesCancersCap Binding ProteinsCell DeathCell Division Kinase 4Cellular ExpansionCellular GrowthCellular Tumor Antigen P53ChemoresistanceComplexCyclin-Dependent Kinase 4DNA BindingDNA Binding DomainDNA Binding InteractionDNA DamageDNA HelicasesDNA InjuryDNA Unwinding ProteinsDNA boundDNA mutationDNA unwinding enzymeDNA-Binding Protein MotifsData BasesDatabasesDrug KineticsDrugsEmerogenesEukaryotic Initiation FactorsEukaryotic Peptide Initiation FactorsEukaryotic Translation Initiation FactorsGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenesGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGrowthHSP-90HSP90HealthHeat-Shock Proteins 90HumanIRESImmunoglobulin Enhancer-Binding ProteinInternal Ribosome Entry SegmentInternal Ribosome Entry SiteKI miceKO miceKnock-in MouseKnock-out MiceKnockout MiceL-SerineMalignant NeoplasmsMalignant TumorMediatingMedicationMessenger RNAMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMissense MutationModern ManMolecular InteractionMolecular Tumor SuppressionMutateMutationNF-kBNF-kappa BNF-kappaBNFKBNeoplasm MetastasisNuclear Factor kappa BNuclear Transcription Factor NF-kBNull MouseOnco-Suppressor GenesOncogenes-Tumor SuppressorsOncogenicOncoprotein p53P53PSK-J3Pathway interactionsPeptidesPharmaceutical PreparationsPharmacokineticsPhosphoprotein P53Phosphoprotein pp53PhosphorylationPilot ProjectsPropertyProtacProtein CleavageProtein PhosphorylationProtein TP53ProteinsProteolysisProteolysis targeting chimericRNA Cap-Binding ProteinsRNA ExpressionRNA-Binding ProteinsReagentRecessive OncogenesResistanceRibosome Entry SiteRoleScaffolding ProteinSecondary NeoplasmSecondary TumorSerineStressTCGATNBCTP53TP53 geneTRP53TestingThe Cancer Genome AtlasTherapeuticTherapeutic AgentsTissue GrowthTranscriptTranscriptionTranscription Factor NF-kBTranscription Factor Proto-OncogeneTranscription factor genesTranslational RegulationTranslationsTumor CellTumor Protein p53Tumor Protein p53 GeneTumor Suppressing GenesTumor SuppressionTumor Suppressor GenesTumor Suppressor Proteinsanalogattenuateattenuatesbio-markersbiologic markerbiomarkerc mycc-myc Genescancer metastasiscancer progressioncell growthchemoresistantchemotherapychemotherapy resistancechemotherapy resistantcmycdata basedrug/agentgain of functiongenome mutationgrowth inhibitory proteinshelicasehsp90 Familyimprovedin silicoinhibitorkappa B Enhancer Binding Proteinknockin micemRNAmRNA Cap Binding ProteinsmRNA Translationmalignancymissense single nucleotide polymorphismmissense single nucleotide variantmissense variantmutantnecrocytosisneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachnuclear factor kappa betaoncosuppressor geneontogenyoverexpressoverexpressionp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypilot studyprotein p53proteolysis targeting chimaeraproteolysis targeting chimeraresistantresponsescreeningscreeningsside effectsmall moleculesocial roletargeted cancer therapytranscription factortranslationtriple-negative breast cancertriple-negative invasive breast carcinomatumortumor cell metastasistumor progressiontumor suppressorv-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog
Description preview
Project Summary/Abstract
Mutation of the tumor suppressor gene TP53 occurs in more than half of human cancers. Mutant p53
is known to actively drives tumor progression, metastasis, and therapy resistance and thus, is
considered as a promising target for cancer therapy. Our pilot studies showed that RNA-binding
protein Rbm38, upon phosphorylation…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click